Michigan is currently home to 2174 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
Recruiting
This is a phase IV, prospective, open label, randomized-controlled study that will compare radial access with state-of-the-art femoral access in patients without ST-segment elevation acute myocardial infarction undergoing cardiac catheterization. Subjects will be randomized 1:1 into 2 treatment groups: radial access and state-of-the-art femoral access. Randomization will be performed in blocks of 50 per site. Similarly, a second sub-randomization will be performed in the femoral access group int... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Patient Satisfaction, Vascular Access Complication
Intra-Corporeal Anastomosis Result in Quicker Return of Bowel Function/Earlier Discharge
Recruiting
Adult patients who are regularly scheduled to undergo a right hemicolectomy via a minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Spectrum Health Medical Group, Grand Rapids, Michigan
Conditions: Colorectal Disorders
Exparel Injection for Postoperative Orbital Pain
Recruiting
After surgery to remove the eye, either by enucleation or evisceration, patients have variable levels of pain for several postoperative days. Some patients have almost no discomfort while others require significant amounts of oral narcotics and report pain of 10 out of 10 on a numerical rating scale. The current operative standard is to infiltrate the eye socket with 0.5% bupivacaine during surgery leading to several hours of postoperative analgesia. In 2011, Pacira Pharmaceuticals released a bu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Michigan Kellogg Eye Institute, Ann Arbor, Michigan
Conditions: Pain, Postoperative
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Recruiting
The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for an average of 4-72 hours In the 1st part of the study approximately half of the participants will r... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
01/21/2025
Locations: Michigan Headache & Neurological Institute, Ann Arbor, Michigan
Conditions: Migraine
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Recruiting
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Lathrup Village, Michigan
Conditions: Excessive Sleepiness, Shift-work Disorder
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
Recruiting
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months. The aim of the study is to see how safe and tolerable mibavademab is when switching from treatment with metreleptin. The study is looking at several other research questions, including: * What side effects may happen from taking mibavademab * How much mibavademab is in the blo... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
01/21/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Generalized Lipodystrophy
Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR)
Recruiting
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: University of Michigan Kellogg Eye Center, Ann Arbor, Michigan
Conditions: Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials
Recruiting
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
01/21/2025
Locations: University of Michigan Kellogg Eye Center, Ann Arbor, Michigan
Conditions: Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
The Breakfast Study
Recruiting
The investigators will conduct an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, very low-carbohydrate breakfast-focused program in 120 adults with type 2 diabetes. The investigators will measure acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/21/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Type 2 Diabetes
No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair
Recruiting
The investigators hypothesize that not prescribing opioids after uncomplicated, outpatient IHR will be non-inferior to prescribing opioids (5 tablets of Oxycodone, 5mg; or surgeon preference for intolerance) with respect to requests for opioid refills. Additionally, the investigators believe there will be no significant difference in postoperative readmission for pain quality of life at 30 days in either group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Corewell Health, Royal Oak, Michigan
Conditions: Postoperative Pain, Inguinal Hernia
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Recruiting
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
01/21/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
Recruiting
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan
Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma